Overview
This research blend combines two synthetic peptides engaging complementary growth hormone axis pathways — CJC-1295 no DAC (a modified GHRH analog) and Ipamorelin (a selective growth hormone secretagogue receptor agonist). The combination has been a subject of research interest investigating the dual-pathway pharmacology of simultaneous GHRH-R and GHSR engagement in preclinical models (Teichman et al., 2006; Raun et al., 1998).
History
The CJC-1295/Ipamorelin combination emerged from research investigating the complementary pharmacology of GHRH receptor and GHSR signaling. Preclinical research has characterized the individual pharmacokinetic and pharmacodynamic profiles of each compound, with research interest focused on their co-administration for dual-pathway GH axis investigation (Sinha et al., 2014).
Structure & Molecular Data
| CAS Number | N/A (synthetic peptide blend) |
| Molecular Formula | Blend: CJC-1295 no DAC (C₁₅₂H₂₅₂N₄₄O₄₂) + Ipamorelin (C₃₈H₄₉N₉O₅) |
| Molecular Weight | Combined MW: CJC-1295 no DAC (3,367.97 g/mol) + Ipamorelin (711.86 g/mol) |
| Amino Acid Count / Structure | Blend of 30-aa GHRH analog (CJC-1295 no DAC) and 5-aa GHSR agonist (Ipamorelin) |
| PubChem CID | CJC-1295 no DAC: 56841945 | Ipamorelin: 9831659 |
| Sequence | See individual compound entries (SM-CJC and SM-IPA) |
| Appearance | Co-lyophilized white powder blend |
| Storage | Store at -20°C. Protect from light. |
| Solubility | Soluble in sterile water and bacteriostatic water |
Compound Class & Mechanism
The two peptides in this blend engage distinct receptor systems within the growth hormone axis. CJC-1295 no DAC binds the GHRH receptor on pituitary somatotrophs, activating Gs-cAMP-PKA signaling. Ipamorelin binds the growth hormone secretagogue receptor (GHSR-1a) on the same cells, activating phospholipase C-mediated calcium signaling.
Research has characterized the individual pathway profiles of each receptor system. GHRH-R and GHSR engage distinct but convergent signaling pathways that have been associated with GH release patterns in preclinical models. Researchers interested in dual-pathway research designs use this blend to simplify single-preparation protocols.
Research Findings
Research on this blend draws from the individual compound literatures on CJC-1295 and Ipamorelin. Published research has documented findings across the following research domains:
Key Research Areas
- Dual-Pathway GH Axis Research: GHRH-R + GHSR combined engagement pharmacology
- Pulsatility Research: pulsatile GH release pattern research in preclinical models
- Receptor Pharmacology: complementary GHRH-R and GHSR signaling research
- Combination Research Protocols: multi-receptor research designs
Collectively, this research blend provides a single-preparation format for protocols investigating dual GHRH-R/GHSR pharmacology.
Research Context
Researchers study this blend as a single-preparation format when research protocols call for co-administration of a GHRH analog with a GHSR agonist. The blend is positioned as a dual-pathway research tool rather than a distinct pharmacological entity.
References
Teichman SL. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. JCEM.
Raun K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.
Sinha DK. et al. (2014). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition. Translational Andrology and Urology.
Ionescu M., Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. JCEM.
| REGULATORY & LEGAL NOTICE
Intended Use. This product is sold exclusively as a research chemical for use in controlled laboratory settings by qualified scientific professionals. It is intended solely for in vitro research, analytical standards, and non-clinical preclinical experimentation. The product is not a drug, dietary supplement, cosmetic, food product, or consumer article of any kind. Prohibited Uses. This product is NOT for use in humans, NOT for veterinary use, NOT for in vivo use in any species, NOT for diagnostic use, NOT for therapeutic use, NOT for food or agricultural use, and NOT for compounding into any preparation intended for administration to humans or animals. Qualified Professionals Only. Purchasers represent that they are qualified scientific professionals, licensed researchers, or authorized personnel at a research institution, and that this product will be handled in accordance with all applicable institutional, federal, state, and local regulations governing research chemicals. Regulatory Notice. The statements made regarding this product have not been evaluated by the U.S. Food and Drug Administration. This product has not been approved by the FDA for any therapeutic, diagnostic, or preventive use. Not a Compounding or Outsourcing Facility. Sirius Molecules is a research chemical supplier. Sirius Molecules is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Legal Compliance. Purchasers are solely responsible for ensuring that their acquisition, possession, handling, and use of this product complies with all applicable laws and regulations in their jurisdiction. |
